These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23817717)

  • 1. Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab.
    Zschiedrich S; Prager EP; Kuehn EW
    Ann Intern Med; 2013 Jul; 159(1):76. PubMed ID: 23817717
    [No Abstract]   [Full Text] [Related]  

  • 2. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
    Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J
    Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome.
    Cañigral C; Moscardó F; Castro C; Pajares A; Lancharro A; Solves P; de la Rubia J; Carpio N; Sanz MA
    Ann Hematol; 2014 Aug; 93(8):1421-2. PubMed ID: 24306089
    [No Abstract]   [Full Text] [Related]  

  • 4. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
    Fakhouri F; Frémeaux-Bacchi V; Loirat C
    Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation.
    Carr R; Cataland SR
    Ann Hematol; 2013 Jun; 92(6):845-6. PubMed ID: 23154867
    [No Abstract]   [Full Text] [Related]  

  • 6. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.
    Christmann M; Hansen M; Bergmann C; Schwabe D; Brand J; Schneider W
    Pediatrics; 2014 Jun; 133(6):e1759-63. PubMed ID: 24843059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical grand rounds: atypical hemolytic uremic syndrome.
    Hodgkins KS; Bobrowski AE; Lane JC; Langman CB
    Am J Nephrol; 2012; 35(5):394-400. PubMed ID: 22517061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
    N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft.
    Alachkar N; Bagnasco SM; Montgomery RA
    Transpl Int; 2012 Aug; 25(8):e93-5. PubMed ID: 22591029
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful discontinuation of eculizumab therapy in a patient with aHUS.
    Pu JJ; Sido A
    Ann Hematol; 2014 Aug; 93(8):1423-5. PubMed ID: 24346709
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.
    Schmidtko J; Peine S; El-Housseini Y; Pascual M; Meier P
    Am J Kidney Dis; 2013 Feb; 61(2):289-99. PubMed ID: 23141475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab. A less burdensome treatment for atypical haemolytic uraemic syndrome?
    Prescrire Int; 2013 Mar; 22(136):68. PubMed ID: 23593689
    [No Abstract]   [Full Text] [Related]  

  • 13. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM; Brophy PD
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3.
    Ferreira E; Oliveira N; Marques M; Francisco L; Santos A; Carreira A; Campos M
    Nefrologia; 2016; 36(1):72-5. PubMed ID: 26541438
    [No Abstract]   [Full Text] [Related]  

  • 15. Eculizumab in atypical hemolytic-uremic syndrome.
    Tanimoto T; Oshima Y; Kami M
    N Engl J Med; 2013 Oct; 369(14):1378-9. PubMed ID: 24088109
    [No Abstract]   [Full Text] [Related]  

  • 16. Eculizumab in atypical hemolytic-uremic syndrome.
    Kistler AD
    N Engl J Med; 2013 Oct; 369(14):1378. PubMed ID: 24088108
    [No Abstract]   [Full Text] [Related]  

  • 17. Eculizumab in atypical hemolytic-uremic syndrome.
    Amadio A; Tejani AM
    N Engl J Med; 2013 Oct; 369(14):1378. PubMed ID: 24088107
    [No Abstract]   [Full Text] [Related]  

  • 18. Eculizumab in atypical hemolytic-uremic syndrome.
    Ring T
    N Engl J Med; 2013 Oct; 369(14):1377-8. PubMed ID: 24088106
    [No Abstract]   [Full Text] [Related]  

  • 19. Eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Loirat C
    N Engl J Med; 2013 Oct; 369(14):1379-80. PubMed ID: 24088105
    [No Abstract]   [Full Text] [Related]  

  • 20. [Eculizumab: effectiveness of a shortened dosing schedule in the treatment of atypical haemolytic uremic syndrome of unknown origin].
    Beye F; Malbranche C; Tramecon D; Pernot C; Zanetta G; Mousson C; Guignard MH; Lazzarotti A
    Therapie; 2013; 68(2):119-22. PubMed ID: 23773354
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.